Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/01/23
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 09/01/20
End: 08/31/23
Due: 08/31/24
Phase: N/A
Priority: Normal
Start: 01/21/22
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 04/01/20
End: 12/31/22
Due: 12/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | NCT05827770 | Yong Chen | user2@example.com | None | 2023-05-01 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |
| Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment | NCT04699214 | Yong Chen | user2@example.com | None | 2020-09-01 | 2023-08-31 | 2024-08-31 | - | - | 2025-07-14 |
| To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma | NCT05106023 | Yong Chen | user2@example.com | None | 2022-01-21 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | NCT04765228 | Yong Chen | user2@example.com | None | 2020-04-01 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |